| Document |
Document Title |
|
JP2004515549A |
Compounds having the general structure:are effective antimicrobial agents.
|
|
JP2004515548A |
Compounds of the following formula:are effective antimicrobial agents.
|
|
JP2004510712A |
The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.
|
|
JP2004509785A |
The invention relates to an optical data medium containing a preferably transparent substrate that is optionally already coated with one or more reflective layers and on the surface of which have been applied: (1) an information layer th...
|
|
JP2004509377A |
The present invention relates to a singly recordable optical data medium using Co-phthalocyanine complexes of the formula (I) In which the groups are defined herein, as light-absorbing compounds in the information layer of optical data m...
|
|
JP2004508356A |
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for m...
|
|
JP2004503500A |
The present invention relates to protoberberine derivatives which inhibit the activity of mitogen-activated protein kinase. More specifically, the present invention is directed to protoberberine derivatives which inhibit the activity of ...
|
|
JP2004502771A |
The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
|
|
JP3487611B2 |
PURPOSE: To obtain new compds. useful as dual inhibitors having inhibitory activity against angiotensin converting enzyme and neutral endopeptidase in the treatment of hypertension, congestive heart failure, hepatocirrhosis, etc. CONSTIT...
|
|
JP2004002454A |
To provide an inhibitor effective for inhibiting enterokinesis sthenia activity caused by a nonsteroidal antiinflammatory, and to provide an antiinflammatory pharmaceutical composition of which the enterokinesis sthenia activity is reduc...
|
|
JP2003535865A |
This invention provides novel caspase inhibitors of formula I: wherein R1 is hydrogen, CHN2, R, or —CH2Y; R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclyl group, or a heterocyclylalkyl group; Y is an electronega...
|
|
JP3453394B2 |
A compound of formula (I) wherein A is a substituent selected from the group consisting of wherein R min is hydrogen or methyl, m is zero or 1 and the @ @ means that the azabicyclic rings may be in the alpha or the beta orientation, and ...
|
|
JP2003528097A |
The present application describes novel beta-amino acid derivatives of formula I:or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specificat...
|
|
JP3420549B2 |
To obtain an anticancer compound in a high yield useful for treating a highly proliferative disorder such as cancer in mammals by using a specific synthetic intermediate. (A) A compound of formula I [R1 and R2 are each a 1-10C alkyl, a 1...
|
|
JP2003171278A |
To provide a new and easy to synthesize apoptosis-inducing agent exhibiting the apoptosis-inducing activity against various cancer cell lines in a lower concentration and also exhibiting cytotoxicity in the lower concentration.This apopt...
|
|
JP3358749B2 |
PURPOSE: To provide a compound which exhibits a desirable green color in the darkened state and is capable of having a useful infrared absorbance at about 780 nm in the near infrared region in the state. CONSTITUTION: There is provided a...
|
|
JP2002338553A |
To obtain a nitrogen-containing heterocyclic compound useful as a functional material, to provide a method for producing the same and to obtain an organic EL element using the compound.This nitrogen-containing heterocyclic compound can e...
|
|
JP2002308876A |
To provide a 4-oxoquinolizine compound having an antibacterial activity.This compound is represented by formula (I) (wherein R1 is H or a carboxy-protecting group; R2, is H, a halogen, a lower alkyl, a lower alkoxy or hydroxy; R3 to R6 a...
|
|
JP3336024B2 |
|
|
JP2002534526A |
The present invention is a novel series of functionalized heterocycles as chemokine receptor modulators of Formula (I) useful as modulators of chemokine receptor activity. The compounds are useful in the treatment and prevention of the A...
|
|
JP2002284779A |
To obtain a compound capable of controlling production of inflammatory cytokine.This compound is represented by general formula (I) {A is a pyrrole ring; R1 is a substitutable aryl or a substitutable heteroaryl; R2 is a substitutable het...
|
|
JP2002226449A |
To provide a charge transfer compound or the like having a hydrazone-bridged heterocyclic group linked through a central bridge group.This charge transfer compound is shown by the formula: (R-Q)n-Y [R is selected from the group consistin...
|
|
JP2002522436A |
Compounds of formula (I) or salt thereof or solvate thereof, in which: m is 1 or 2; n is 1 or 2; X is CH or N; Y is selected from hydrogen, halogen, cyano, CF3, alkyl or alkoxy; R<1>, which may be at any position within the saturated rin...
|
|
JP2002522435A5 |
|
|
JP2002522435A |
The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily pr...
|
|
JP2002521337A |
Benzo[b]quinolizidine and benzo[f]indolizidine derivatives are provided which are useful for the treatment of Alzheimer's disease, senile dementia or other conditions characterized by memory loss. Pharmaceutical compositions containing t...
|
|
JP2002201130A |
To obtain an agent capable of strongly inhibiting the formation of inflammatory cytokines and/or matrix metalloproteases such as IL-6, MMP-1 and PGE2 which are causes of various kinds of inflammatory diseases.This inhibitor of the format...
|
|
JP2002521334A |
The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus in...
|
|
JP2002520394A |
The invention concerns a pharmaceutical composition having an activity on the proliferation of clonogenic cells in tumours and comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia) wherein: X,...
|
|
JP2002520412A |
Disclosed herein are compounds selective for a 5-HT1D receptor, the compounds having the general formula (I):Also disclosed is the use of these compounds as pharmaceuticals to treat indications where stimulation of a 5-HT1D receptor is i...
|
|
JP2002519348A |
The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1f receptors and inhibiting protein extravasation in a mammal.
|
|
JP2002179678A |
To obtain a new synthetic antimicrobial agent.This quinolizine compound is a compound of formula (I) (wherein, R1 denotes an alkyl, or the like; R2 denotes an alkyl, a 1-6C alkoxy, or the like; R3 denotes H or a halogen; R4 denotes H, a ...
|
|
JP3294611B2 |
PCT No. PCT/GB92/01649 Sec. 371 Date Jul. 28, 1994 Sec. 102(e) Date Jul. 28, 1994 PCT Filed Sep. 9, 1992 PCT Pub. No. WO93/05038 PCT Pub. Date Mar. 18, 1993 (I) (a) (b) (c) The use of a compound of formula (I) or pharmaceutically accepta...
|
|
JP2002137918A |
To provide a method of synthesizing a zeolite especially SSZ-35, and a new organic template compound and its manufacturing method.Zeolite SSZ-35 is manufactured by the hydrothermal synthesis of a dry gel method. New compound cis, cis, ci...
|
|
JP2002128674A |
To obtain an inhibitor for damages to intestine caused by nonsteroidal anti-inflammatory drugs.This inhibitor is used for damages to intestine caused by nonsteroidal anti-inflammatory drugs such as diclofenac sodium, loxoprofen sodium, i...
|
|
JP2002506867A5 |
|
|
JP2002505318A |
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and are defined variables:Such compounds and their pharmaceutically acceptable salts, multi...
|
|
JP3254773B2 |
PURPOSE: To provide the subject new compound useful in the field of dye, polymer coloring material, dichroic pigment for liquid crystal, etc., photo-sensitive material for electrophotography such as electrophotographic printer, recording...
|
|
JP3243212B2 |
To obtain a medicinal agent containing the subject new compound as active ingredient, to be used in treating tachykinin-involved pathological phenomena such as pain, allergy, inflammation, circulatory dysfunction, digestive tract disorde...
|
|
JP2001527074A |
The present invention refers to benzoÄcÜquinolizines derivatives, fully and partially saturated, having formula (I) and their pharmaceutically acceptable salts which proves useful for pharmaceutical and agricultural use being capable o...
|
|
JP2001335485A |
To provide a prophylactic or an improving means effective against dyschromia accompanied by inflammations or dyschromia such as ephelides.This skin care preparation is obtained by including berberine, a berberine derivative and/or a phys...
|
|
JP2001335713A |
To obtain a novel azo compound having a good hue and excellent fastness to light and a tautomer of the same.Provided are an azo compound represented by formula (1) (wherein R1 is an alkyl or an aryl; R2, R3, R4, and R5 are each hydrogen,...
|
|
JP2001326080A |
To provide a white color emitting organic electroluminescent element with single luminous layer.For the white color emitting organic electroluminescent element obtained by laminating an anode, a hole carrier layer composed of organic mat...
|
|
JP2001316379A |
To obtain a compound useful as a functional material, and further to provide a method for producing the compound, and an organic EL element by using the compound.This compound is represented by formula (I) or (II) (wherein, X1 and X2 are...
|
|
JP2001521034A |
The invention concerns 2-aminomethyl-benzo[a]quinolizidine derivatives, corresponding to general formula (I) in which: R1 represents either a hydrogen atom or a branched, linear or cyclic C1-C4 alkyl group, a branched, linear or cyclic C...
|
|
JP2001521529A |
This invention provides novel 5-HT1F agonists of the Formula in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
|
|
JP2001247564A |
To provide a compound capable of suppressing the formation of inflammatory cytokine.The objective compound is expressed by general formula (I) {A is pyrrole ring; R1 is a (substituted)aryl or a (substituted)heteroaryl; R2 is a (substitut...
|
|
JP2001513104A |
A process for the preparation of a compound having the formula: wherein R1, R2, R3, R4, and R5 are defined, from an enamine by chain expansion and ring closure followed by additional derivatization, treatment with a 3-alkoxyl-acryloyl co...
|
|
JP2001512725A |
A quinolizine carboxylic acid derivative of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1 and R2 have the same meanings the as defined in the specification.
|
|
JP2001511433A |
Disclosed are compositions of benzo(c)quinolizine derivatives and methods for promoting plant and seed growth. The compounds are benzo[c]quinolizine derivatives which exert an inhibiting effect on the 5-alpha-reductase enzymes. The compo...
|
